Verma Shivani, Utreja Puneet
Department of Pharmaceutics, Rayat-Bahra College of Pharmacy, Hoshiarpur, Punjab 146001, India.
I. K. Gujral Punjab Technical University, Jalandhar, Punjab 144601, India.
Asian J Pharm Sci. 2019 Mar;14(2):117-129. doi: 10.1016/j.ajps.2018.05.007. Epub 2018 Aug 16.
Occurrence of skin fungal infections is increasing nowadays and their presence is more prominent in patients suffering from immunocompromised diseases like AIDS. Skin fungal infections are a major cause of visits by patients to dermatology clinics. Although, a large number of antifungal agents are available for treatment of skin fungal infections, but, their toxic profile and physicochemical characteristics reduce therapeutic outcome. When these antifungal agents are delivered topically using conventional formulations like creams and gels, they may cause various side effects like redness, burning, and swelling at the site of application. Therefore, various vesicular formulations (phospholipid based or non phospholipid based) have been explored by pharmaceutical scientists to treat skin fungal infections topically. Vesicular formulation explored for the purpose are liposomes, ethosomes, transfersomes, transethosomes, niosomes, spanlastics, oleic acid vesicles, and nanoparticles. These formulations show various advantages like bioavailability enhancement of bioactives, high skin permeation power, no side effects at application site, dosing frequency reduction, and sustained drug release. Therefore, in the present article, we have discussed about the utility of various vesicular nanocarrier systems to treat skin fungal infections.
如今皮肤真菌感染的发生率正在上升，并且在患有如艾滋病等免疫功能低下疾病的患者中更为突出。皮肤真菌感染是患者前往皮肤科诊所就诊的主要原因。尽管有大量抗真菌药物可用于治疗皮肤真菌感染，但是它们的毒性特征和物理化学性质降低了治疗效果。当使用乳膏和凝胶等传统制剂局部递送这些抗真菌药物时，它们可能会在应用部位引起各种副作用，如发红、灼烧和肿胀。因此，药物科学家已经探索了各种囊泡制剂（基于磷脂或非基于磷脂）来局部治疗皮肤真菌感染。为此目的探索的囊泡制剂有脂质体、醇质体、传递体、转醇质体、非离子型脂质体、Spanlastics、油酸囊泡和纳米颗粒。这些制剂具有各种优点，如生物活性物质的生物利用度提高、高皮肤渗透能力、在应用部位无副作用、给药频率降低和药物持续释放。因此，在本文中，我们讨论了各种囊泡纳米载体系统在治疗皮肤真菌感染中的效用。
